ImmuCell (ICCC)

Executive Summary

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company focused on animal health, particularly for dairy and beef cattle. The company's lead product, First Defense®, is a USDA-licensed treatment containing hyperimmune antibodies that prevent enteric colibacillosis (scours) in newborn calves. ImmuCell also markets Wipe Out® Dairy Wipes for teat sanitation. The company's pipeline centers on Re-Tain™, a novel therapy for subclinical mastitis in lactating dairy cows, which is currently under FDA review. Re-Tain™ represents a significant market opportunity as it targets a widespread and costly disease that currently lacks effective treatment options. ImmuCell's in-house manufacturing and direct sales force provide operational control and margin potential. Though the company is small-cap, its proven commercial product and late-stage pipeline catalyst position it for potential growth.

Upcoming Catalysts (preview)

• Q4 2026FDA Decision on Re-Tain™ for Subclinical Mastitis60% success
• Q3 2026Q2 2026 Earnings and Revenue Update from First Defense® Sales90% success